EN
ENTA.US Enanta Pharmaceuticals Inc
- Market cap
- USD 320M
- P/E
- -
- P/B
- 3.22x
- ROE
- -58.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.
Is ENTA.US undervalued?
Graham numberThe Graham number of Enanta Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Enanta Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Enanta Pharmaceuticals Inc yet.
Enanta Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the t…
Full company profileEnanta Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Enanta Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 88.3M | 103M | 207M | 205M | 122M | 97.1M | 86.2M | 79.2M | 67.6M | 65.3M | 66.8M |
| Gross Profit | 88.3M | 103M | 207M | 205M | 122M | 97.1M | 86.2M | 79.2M | 67.6M | 60.7M | 65.2M |
| Operating Income | 30.8M | 24.6M | 88.3M | 36.7M | -41.6M | -110M | -124M | -137M | -122M | -85.3M | -53.8M |
| EBITDA | 32.5M | 26.8M | 90.8M | 40.0M | -38.0M | -106M | -119M | -123M | -105M | -70.8M | -40.4M |
| Net Income | 21.7M | 17.7M | 72.0M | 46.4M | -36.2M | -79.0M | -122M | -134M | -116M | -81.9M | -59.4M |
| EPS | 1.13 | 0.91 | 3.48 | 2.21 | -1.81 | -3.92 | -5.91 | -6.38 | -5.48 | -3.84 | -2.04 |
| Balance Sheet | |||||||||||
| Total Assets | 281M | 327M | 414M | 490M | 491M | 441M | 381M | 462M | 377M | 281M | 297M |
| Total Liabilities | 11.3M | 25.0M | 20.5M | 27.3M | 35.2M | 41.4M | 59.3M | 246M | 248M | 216M | 196M |
| Shareholders' Equity | 270M | 302M | 394M | 462M | 456M | 399M | 321M | 217M | 129M | 64.7M | 101M |
| Cash & Short-term Investments | 210M | 224M | 309M | 335M | 387M | 244M | 249M | 370M | 248M | 189M | 190M |
| Total Debt | 690K | 1.22M | 293K | 200K | 9.58M | 6.84M | 26.7M | 26.5M | 226M | 201M | 55.7M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 35.8M | 52.7M | 29.2M | 71.4M | 7.09M | -70.0M | -84.8M | -103M | -78.8M | -19.3M | -38.4M |
| Capital Expenditure | 4.74M | 2.51M | 2.98M | 5.42M | 1.45M | 750K | 2.13M | 9.06M | 17.9M | 12.9M | 220K |
| Free Cash Flow | 31.1M | 50.1M | 26.2M | 66.0M | 5.64M | -70.7M | -86.9M | -112M | -96.7M | -32.2M | -38.7M |
| Ratios | |||||||||||
| ROE | 8.0% | 5.9% | 18.3% | 10.0% | -7.9% | -19.8% | -37.9% | -61.7% | -90.1% | -126.5% | -58.7% |
| ROA | 7.7% | 5.4% | 17.4% | 9.5% | -7.4% | -17.9% | -32.0% | -28.9% | -30.8% | -29.2% | -20.0% |
| Net Profit Margin | 24.5% | 17.2% | 34.8% | 22.6% | -29.5% | -81.4% | -141.3% | -169.0% | -171.6% | -125.4% | -88.8% |
| Debt to Equity | 0.00x | 0.00x | 0.00x | 0.00x | 0.02x | 0.02x | 0.08x | 0.12x | 1.75x | 3.11x | 0.55x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Enanta Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | USD 2.66M | 0.13 | 5.7% |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Enanta Pharmaceuticals Inc
- Insiders 4.67%
- Institutions 93.23%
- Public & others 2.10%
- Shares outstanding 29.1M
- Free float 22.5M
Top funds holding ENTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 877K | 3.01% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 720K | 2.47% | 0.00% | Oct 2026 |
| BlackRock Health Sciences Opps Inv A | 492K | 1.69% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 310K | 1.07% | +0.74% | Aug 2026 |
| Vanguard Strategic Small-Cap Equity Inv | 281K | 0.96% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 215K | 0.74% | -0.19% | Oct 2026 |
| Vanguard Strategic Equity Inv | 181K | 0.62% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 165K | 0.57% | +1.13% | Sep 2026 |
| BlackRock Advantage Small Cap Core Instl | 146K | 0.50% | +16.66% | Sep 2026 |
| Vanguard Explorer Inv | 141K | 0.48% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 137K | 0.47% | 0.00% | Oct 2026 |
| Vanguard VIF Small Co Gr | 136K | 0.47% | 0.00% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 136K | 0.47% | +0.24% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 131K | 0.45% | -0.38% | Oct 2026 |
| Fidelity Extended Market Index | 123K | 0.42% | -8.32% | Sep 2026 |
| iShares Micro-Cap ETF | 86.1K | 0.30% | 0.00% | Oct 2026 |
| Schwab Small-Cap Equity | 76.7K | 0.26% | 0.00% | Sep 2026 |
| BlackRock Health Sciences Term Trust | 69.7K | 0.24% | 0.00% | Jun 2026 |
| Schwab Small Cap Index | 69.0K | 0.24% | 0.00% | Sep 2026 |
| DFA U.S. Small Cap I | 64.9K | 0.22% | 0.00% | Sep 2026 |
Top institutions holding ENTA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jupiter Topco LLC | 3.65M | 12.55% | 0.00% | Jun 2026 |
| BlackRock Inc | 3.24M | 11.14% | +4.53% | Jun 2026 |
| Krensavage Asset Management, LLC | 2.87M | 9.84% | 0.00% | Jun 2026 |
| Farallon Capital Management, L.L.C. | 2.42M | 8.30% | -15.80% | Jun 2026 |
| Deep Track Capital, LP | 1.44M | 4.96% | -26.20% | Jun 2026 |
| ADAR1 Capital Management LLC | 1.34M | 4.62% | +2,517.97% | Jun 2026 |
| Vanguard Capital Management, LLC | 1.21M | 4.16% | +2.86% | Jun 2026 |
| Spruce Street Capital LP | 1.09M | 3.74% | +16.74% | Jun 2026 |
| Acadian Asset Management LLC | 1.08M | 3.70% | +22.53% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.01M | 3.47% | +6.60% | Jun 2026 |
| Geode Capital Management, LLC | 777K | 2.67% | +7.11% | Jun 2026 |
| Millennium Management LLC | 644K | 2.21% | -27.00% | Jun 2026 |
| State Street Corp | 576K | 1.98% | +2.49% | Jun 2026 |
| Renaissance Technologies Corp | 558K | 1.91% | -16.18% | Jun 2026 |
| Hillsdale Investment Management Inc. | 468K | 1.61% | +7.46% | Jun 2026 |
| The Goldman Sachs Group Inc | 465K | 1.60% | +75.28% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 316K | 1.08% | +2.01% | Jun 2026 |
| Charles Schwab Investment Management Inc | 301K | 1.03% | +2.10% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 291K | 1.00% | +3.02% | Sep 2026 |
| Northern Trust Corp | 260K | 0.89% | +7.77% | Jun 2026 |
Enanta Pharmaceuticals Inc company profile
- Company name
- Enanta Pharmaceuticals Inc
- Ticker
- ENTA.US
- Exchange
- USA Stocks
- Listed since
- Mar 21, 2013
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 120
- Fiscal year end
- September
- Address
- 4 Kingsbury Avenue, Watertown, MA, United States, 02472
- Phone
- 617 607 0800
- Website
- enanta.com
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
Enanta Pharmaceuticals Inc management
10- Dr. Jay R. Luly Ph.D.President, CEO & Director · born 1956
- Dr. Yat Sun Or Ph.D.Chief Scientific Officer · born 1952
- Dr. Scott T. Rottinghaus M.D.Chief Medical Officer · born 1974
- Mr. Harry R. Trout IIIVP of Finance & Interim Principal Financial Officer · born 1969
- Ms. Tara Lynn Kieffer Ph.D.Chief Operating Officer · born 1978
- Ms. Kathleen S. Capps CPAExecutive Director of Accounting, Controller & Interim Principal Accounting Officer · born 1985
- Ms. Jennifer VieraExecutive Director of Investor Relations & Corporate Communications
- Mr. Matthew P. Kowalsky J.D.Chief Legal Officer & Corporate Secretary · born 1973
- Mr. Nathaniel S. Gardiner J.D.Consultant · born 1954
- Mr. Brendan LuuChief Business Officer · born 1975